Hypertrophic cardiomyopathy (HCM) is a common hereditary cardiac disorder characterized by abnormal thickening of the left ventricular walls [
1]. If not treated promptly, it can progress to heart failure (HF) [
2,
3]. According to statistical data, one in every 3200 individuals is affected by HCM, and approximately two-thirds of HCM patients progress to obstructive HCM (oHCM) [
4,
5]. In this pathological condition, asymmetric septal hypertrophy of the ventricular septum impedes the outflow of blood from the left ventricle, thereby leading to an elevated pressure gradient in the left ventricular outflow tract (LVOT) [
6,
7]. To combat cardiac hypertrophy, a variety of therapeutic options have been investigated, such as angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), angiotensin receptor neprilysin inhibitors (ARNI),
β-blockers, mineralocorticoid receptor antagonists (MRA), sodium-dependent glucose transporters 2 inhibitors (SGLT2i), and soluble guanylate cyclase (sGC) stimulators [
8–
10]. However, these approaches can alleviate symptoms and enhance quality of life, but are incapable of providing a complete cure [
11,
12]. Researchers have found that cardiac myosin mutations-induced hypercontractility leads to activation of signaling pathways that cause hypertrophy of the heart, fibrosis, and myofilament disarray [
13]. Therefore, direct inhibition of cardiac sarcomere contractility may be a viable approach to treat HCM.
Mavacamten (MYK-461) was the first small molecule allosteric inhibitor of cardiac myosin approved by the U.S. Food and Drug Administration (FDA) for treating oHCM in 2022 [
14,
15]. It modulates cardiac contractility by selectively targeting the myosin-S1 motor and interfering with multiple stages of the myosin chemomechanical cycle to inhibit sarcomere force production [
16,
17]. In addition to its inhibitory effect on cardiac myosin ATPase activity, MYK-461 further ameliorates hypercontractility and LVOT obstruction by reducing actin-myosin cross-bridge formation and attenuating sarcomeric hyperactivation [
18]. This dual mechanism not only decreases excessive systolic force generation but also improves diastolic relaxation, thereby mitigating the pathological hemodynamic consequences of HCM. Despite demonstrated clinical benefit of MYK-461 in oHCM patients, serious side effects were also observed [
19]. For example, the human half-life (
t1/2) of MYK-461 is quite long, approximately ranging from 7 days to 9 days [
20,
21]. Therefore, it takes about 6 weeks for the drug concentration to reach a stable level, which may lead to various safety issues caused by drug accumulation [
22,
23]. Additionally, MYK-461 shows CYP3A4 and CYP2B6 induction in human hepatocytes, suggesting that it may cause drug-drug interactions (DDIs) due to the different clearance mechanisms of concomitant medications [
24–
26]. Therefore, the administration of MYK-461 requires strict adherence to a complex dose escalation regimen and thorough risk assessment [
27].
To address the issues with MYK-461, MyoKardia company designed and synthesized a series of bicyclic pyrimidinedione compounds by the intramolecular cyclization of MYK-461, and developed the second therapeutic candidate MYK-224, which exhibited shorter half-life and reduced risk of CYP induction [
28,
29]. The phase Ⅰ clinical trial of MYK-224 in healthy volunteers has been completed, and further clinical trials are currently underway [
30]. These findings suggest that cyclization modification is a feasible strategy for improving the PK properties of MYK-461. Furthermore, aficamten (CK-274), a novel cardiac myosin inhibitor developed by cytokinetics for the treatment of symptomatic oHCM, is also currently in phase Ⅲ clinical trials [
31,
32]. Compared with its predecessor MYK-461, CK-274 has more stable PK properties and a lower potential risk of drug interactions. Overall, although MYK-461 has been approved for the treatment of HCM, its safety and efficacy still need to be improved. Therefore, the discovery of novel cardiac myosin inhibitor with improved PK properties and safety is of great significance (Fig. S1 in Supporting information).
In this study, a series of novel cardiac myosin inhibitors were designed and synthesized by ingeniously cyclizing the ethylbenzene part of MYK-461 to form a tetrahydronaphthalene ring. Through systematic biological activity and pharmacokinetic (PK) properties evaluations, were discovered a novel and potent cardiac myosin inhibitor Z5–11, which effectively alleviated cardiac hypertrophy and exhibited high oral bioavailability and a reasonable half-life (
Fig. 1A).
To facilitate the rational design, we first predicted the binding mode of MYK-461 to cardiac myosin by molecular docking. Since the crystal structure of MYK-461 to cardiac myosin has not been reported, the crystal structure of blebbistatin bound to an analogous myosin Ⅱ from
Dictyostelium discoideum (PDB: pdb:1YV3) was used for the docking studies [
33,
34]. As shown in
Figs. 1B and C, MYK-461 showed excellent shape complementarity with the binding pocket of myosin Ⅱ, and the pyrimidone scaffold formed three key hydrogen bonds with Leu263, Lys265 and Ser266. The isopropyl and benzylamine groups were located in hydrophobic cavity A and B, respectively. The volume of cavity B was larger, suggesting that structural modification around the benzylamine group was feasible, and increasing the volume of the substituents would better occupy the hydrophobic cavity. Based on the above analysis and in combination with the patent protection scope of MYK-461, we designed a series of new cardiac myosin inhibitors by cyclizing the ethylbenzene of MYK-461 to a tetrahydronaphthalene ring. To verify rationality of our design, the docking study of designed compound Z5–8 with myosin was performed. As shown in
Figs. 1D and E, the pyrimidone scaffold of Z5–8 could also form three key hydrogen bonds with Leu263, Lys265 and Ser266, and the spatial configuration of the tetrahydronaphthalene ring was basically consistent with the ethylbenzene of MYK-461.
Encouraged by this promising result, a series of indolone derivatives bearing isoxazole hydrophobic cap were designed and synthesized by varying the R1, R2 and R3 substituents. To assess the potential cardiac myosin inhibitory activity of these designed compounds, we developed an in vitro assay for detecting the myosin ATPase inhibitory activity based on the principle that MYK-461 binds to the myosin-S1 motor domain and inhibits its ATPase activity. The results were shown in Tables S1 and S2 (Supporting information) and the structure-activity relationships (SARs) were detailly summarized.
Based on the SARs study, compounds Z5–3 and Z5–11 with higher myosin ATPase inhibition rate were chosen for further determination of the half maximal inhibitory concentration (IC
50) value, and MYK-461 and CK-274 were used as positive controls. As shown in
Figs. 2A–D, Z5–11 displayed excellent myosin ATPase inhibitory activity with the IC
50 values of 0.66 µmol/L, which was much stronger than that of MYK-461 (IC
50: 1.13 µmol/L) and CK-274 (IC
50: 1.43 µmol/L), respectively. Besides, Z5–3 showed similar myosin ATPase inhibitory activity (IC
50: 1.12 µmol/L) to MYK-461. Furthermore, the binding affinity of Z5–11 to cardiac myosin was detected by surface plasmon resonance analysis. The result revealed that Z5–11 exhibited stronger binding affinity than MYK-461 with the dissociation constant (
Kd) values of 1.02 and 4.94 µmol/L, respectively (
Figs. 2E and F). Taken together, the above results suggest that Z5–11 is a potent myosin ATPase inhibitor.
To better understand the binding mode between Z5–11 and myosin, we conducted a molecular docking study. As shown in
Fig. 2G, Z5–11 exhibited excellent complementarity in the binding pocket of myosin Ⅱ (PDB: pdb:1YV3). In detail, the pyrimidone scaffold formed two key hydrogen bonds with Leu263 and Lys265. The oxygen atom on the pyran ring form a hydrogen bond with Lys423. The tetrahydronaphthalene ring occupied the hydrophobic cavity. To understand the binding stability of Z5–11 to myosin Ⅱ, a molecular dynamic (MD) simulation at 100 ns was carried out using the Desmond Module of Schrödinger Maestro software (
Fig. 2H). The protein backbone root-mean-square derivation (RMSD) plot analysis of myosin Ⅱ-Z5–11 complex revealed that a stable RMSD of 3.2 Å was achieved after 50 ns of simulation. Furthermore, the binding free energy was calculated using the molecular mechanics generalized Born surface area (MM-GBSA) method. As depicted in
Fig. 2I, the total binding free energy between Z5–11 and myosin Ⅱ was −124.70 kcal/mol, and the higher van der Waals energy (−67.88 kcal/mol) and nonpolar solvation energy (−56.06 kcal/mol) made major contributions to the binding free energy.
Encouraged by the potent myosin ATPase inhibitory activity, the effects of Z5–11 and Z5–3 on the contraction of myocardial cells and myocardial hypertrophy were evaluated. We isolated neonatal rat cardiomyocytes (NRCMs) and placed cell suspension in a perfusion chamber integrated with the microscope stage, followed by synchronized application of electric field stimulation and a certain concentration of drug intervention. The contraction amplitude and other contraction indicators of myocardial cells before and after drug administration were detected using the IonOptix measurement system to calculate the inhibition rate of compounds on myocardial cell contraction. The results illustrated the inhibitory effects of Z5–11 and Z5–3 on the contractility of NRCMs were summarized in Table S3 (Supporting information). A significant reduction in myocyte contractility as measured by myocyte length was observed upon treatment with these two compounds relative to a predose measurement. More exactly, Z5–11 demonstrated dose-dependent inhibitory effect on myocardial cell contraction, achieving an inhibition rate of 80.7% at a concentration of 1 µmol/L, significantly surpassing that of MYK-461 (58.7%).
To more directly observe the ameliorative effects of Z5–11 and Z5–3 on cardiac hypertrophy
in vitro, we isolated NRCMs and investigated the effects of these compounds (0.1, 1, 10 µmol/L) on NRCMs under Ang Ⅱ stimulation (
Fig. 3A). As expected, hypertrophic markers (
Nppa, Nppb) and fibrosis markers (
Col1a1,
Acta2) were significantly down-regulated after Z5–11 and Z5–3 treatment compared to Ang Ⅱ group (
Figs. 3B–E). Moreover, both Z5–11 and Z5–3 (1 µmol/L) treatments markedly attenuated Ang Ⅱ-induced cardiomyocyte hypertrophy, as demonstrated by cytoskeletal analysis of myocardial cells (
Fig. 3F). These results strongly suggest that Z5–11 and Z5–3 can alleviate Ang Ⅱ-induced cardiac hypertrophy
in vitro.
Prior to the in vivo efficacy study, we evaluated the in vitro safety of Z5–11, Z5–3 and MYK-461. Rat myocardial cells H9C2 were cultured and treated with varying concentrations of these compounds, followed by cytotoxicity assessment using the cell counting kit-8 (CCK-8) assay. The results demonstrated that H9C2 cell viability was markedly reduced at the concentration of 100 µmol/L after Z5–3 and MYK-461 treatments, whereas Z5–11 showed no significant cytotoxicity even at the concentration as high as 100 µmol/L (Fig. S2 in Supporting information). These results indicated that the safety of Z5–11 has been significantly improved compared to MYK-461.
To investigate whether the
in vivo metabolisms of Z5–11 and Z5–3 have been improved, we evaluated the PK parameters of these two compounds in Sprague Dawley rats through intravenous injection (i.v., 2.5 mg/kg) and oral administration (p.o., 5 mg/kg). As depicted in
Table 1, the half-lives of Z5–11 and Z5–3 were 2.74 h and 4.25 h, respectively, which were significantly shorter compared to MYK-461 (
t1/2 = 8.2 h) [
20]. Among which, Z5–11 showed the optimal PK properties with high plasma exposure, reasonable half-life time (
t1/2 = 2.74 h), and high oral bioavailability (
F = 105.2%). Overall consideration of the myosin inhibitory activity, safety and PK properties, Z5–11 was selected for further biological evaluation
in vivo.
To investigate the cardioprotective effects of Z5–11 on mice with cardiac hypertrophy, we created mouse models through transverse aortic constriction (TAC) and administered Z5–11 for 4 weeks (
Fig. 4A). To comprehensively evaluate cardiac function and myocardial remodeling in each group, we performed B-mode echocardiography to assess global cardiac structure and M-mode imaging to measure left ventricular wall thickness at end-systole and end-diastole (
Fig. 4B).
Echocardiographic assessment demonstrated that Z5–11-treated mice exhibited attenuated cardiac dilation and improved functional preservation after TAC, as evidenced by key parameters including: left ventricular end-diastolic anterior wall thickness (LVAWd), left ventricular end-systolic anterior wall thickness (LVAWs), left ventricular posterior wall diameter in diastole (LVPWd), left ventricular posterior wall diameter in systole (LVPWs), ejection fraction (EF), left ventricular mass (LV mass), and fractional shortening (FS) (
Figs. 4C–I).
Furthermore, morphological analysis revealed that TAC surgery induced significant cardiac hypertrophy, which was markedly attenuated by Z5–11 and MYK-461 treatment (
Figs. 4J–L). In detail, WGA staining confirmed cardiomyocyte hypertrophy, and Masson staining detected fibrosis in TAC-treated mouse heart tissue (
Fig. 4M). While Z5–11 and MYK-461 treatment effectively attenuated cardiac inflammation and fibrosis, as evidenced by histological staining (
Fig. 4M). Additionally, Z5–11 and MYK-461 significantly suppressed TAC-induced expression of fetal cardiac genes (atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP)) and fibrosis markers (
Figs. 4N and O). Collectively, these results demonstrated that Z5–11 had a significant protective effect on TAC-induced cardiac hypertrophy and fibrosis. All experimental animal protocols were reviewed and approved by Nanjing University of Chinese Medicine Animal Ethics Committee (approval No. 202205A056), complying with Guidelines for the Care and Use of Laboratory Animals.
In summary, through rational structural optimization and systematic biological evaluation, we identified a novel and potent cardiac myosin inhibitor Z5–11. It not only displayed stronger myosin ATPase inhibitory activity, but also had a significant inhibitory effect on cardiac myocyte contraction, and can alleviate Ang Ⅱ-induced cardiac hypertrophy. Notably, the safety and of PK parameters of Z5–11 were significantly improved compared to MYK-461. Moreover, Z5–11 can effectively ameliorate TAC-induced cardiac dysfunction and cardiac hypertrophy and remodeling in mice. These results strongly supported the potential of Z5–11 as a therapeutic approach for HCM.
PDF
Full
73
40
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
